Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 133

Sort by

Sort Order Select

Journal Articles

Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)

Blood (2024) 144 (Supplement 1): 1820.

https://doi.org/10.1182/blood-2024-209193

Published: 2024

Journal Articles

Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation

Courtney D. DiNardo, Kelly S. Chien, Jillian Mullin, Danielle Hammond, Jeremy Ramdial, Tapan M. Kadia, Fadi G. Haddad, Musa Yilmaz, Koji Sasaki, Ghayas C. Issa, Koichi Takahashi, Elizabeth J. Shpall, Farhad Ravandi, Naval Daver, Hagop Kantarjian

Blood (2024) 144 (Supplement 1): 1527.2.

https://doi.org/10.1182/blood-2024-208771

Published: 2024

Journal Articles

Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes

Mehmet Sevki Uyanik, Guillermo Garcia-Manero, Abhishek Maiti, Farhad Ravandi, Kelly S. Chien, Danielle Hammond, Alexandre Bazinet, Heather Schneider, Stephany Hendrickson, Sherry Pierce, Hagop M. Kantarjian, Naveen Pemmaraju, Guillermo Montalban-Bravo

Blood (2024) 144 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2024-207503

Published: 2024

Journal Articles

A Single-Cell T-Cell Reference Map Delineates the Biological Landscape of CD4 + T Cells in Myelodysplastic Syndromes Under Venetoclax Therapy

Juan Jose Rodriguez Sevilla, Yang Liu, Irene Ganan-Gomez, Vera Adema, Kelly S. Chien, Guillermo Montalban-Bravo, Natthakan Thongon, Guillermo Garcia-Manero, Rashmi Kanagal-Shamanna, Sanam Loghavi, Hui Yang, Linghua Wang, Simona Colla

Blood (2024) 144 (Supplement 1): 50.

https://doi.org/10.1182/blood-2024-202641

Published: 2024

Journal Articles

Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse

Nicholas J. Short, Hagop Kantarjian, Nitin Jain, Koichi Takahashi, Ken Furudate, Jayastu Senapati, Fadi G. Haddad, Omer Karrar, Tapan M. Kadia, Kelly S. Chien, Koji Sasaki, Eitan Kugler, Rebecca Garris, Farhad Ravandi, Elias Jabbour

Blood (2024) 144 (Supplement 1): 837.

https://doi.org/10.1182/blood-2024-206602

Published: 2024

Journal Articles

A Phase I/II Study of Mini-Hyper-CVD, Venetoclax and Navitoclax in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Nicholas J. Short, Hagop Kantarjian, Nitin Jain, Jayastu Senapati, Fadi G. Haddad, Omer Karrar, Kelly S. Chien, Eitan Kugler, Adaeze Elechi, Regina Abramova, Min Zhao, Rebecca Garris, Marina Konopleva, Farhad Ravandi, Elias Jabbour

Blood (2024) 144 (Supplement 1): 4198.

https://doi.org/10.1182/blood-2024-206487

Published: 2024

Journal Articles

Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)

Caitlin R Rausch, Emmanuel Almanza-Huante, Wei-Ying Jen, Guillermo Montalban-Bravo, Farhad Ravandi, Kelly S. Chien, Nicholas J. Short, Naval Daver, Courtney D. DiNardo, Abhishek Maiti, Joseph E. Jabbour, Ghayas C. Issa, Guillermo Garcia-Manero, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 4262.

https://doi.org/10.1182/blood-2024-203831

Published: 2024

Journal Articles

Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML

Julie Braish, Guillermo Montalban-Bravo, Farhad Ravandi, Nicholas J. Short, Tapan M. Kadia, Maro Ohanian, Kelly S. Chien, Lucia Masarova, Koji Sasaki, Musa Yilmaz, Naval Daver, Gautam Borthakur, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 3209.

https://doi.org/10.1182/blood-2024-208536

Published: 2024

Journal Articles

Outcomes of Patients with Treated Secondary AML: A High Risk Subtype of AML Arising from Previously Treated Myeloid Neoplasms That Warrants an Independent Prognostic Designation

Jayastu Senapati, Hagop M. Kantarjian, Guillermo Garcia-Manero, Nicholas J. Short, Fadi G. Haddad, Naval Daver, Courtney D. DiNardo, Gautam Borthakur, Joseph E. Jabbour, Naveen Pemmaraju, Amin M. Alousi, Elizabeth J. Shpall, Alexandre Bazinet, Kelly S. Chien, Danielle Hammond, Sherry Pierce, Farhad Ravandi, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 4251.

https://doi.org/10.1182/blood-2024-208121

Published: 2024

Journal Articles

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Blood (2024) 144 (Supplement 1): 446.

https://doi.org/10.1182/blood-2024-203938

Published: 2024

Journal Articles

A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 734.

https://doi.org/10.1182/blood-2024-203459

Published: 2024

Journal Articles

Older Age and TP53 Mutations Are Predictors for the Development of Therapy-Related Myeloid Neoplasms in Adults Undergoing Frontline Therapy for Acute Lymphoblastic Leukemia

Roberta Santos Azevedo, Hagop M. Kantarjian, Koichi Takahashi, Cedric Christophe Nasnas, Sanam Loghavi, Nitin Jain, Fadi G. Haddad, Jayastu Senapati, Ghayas C. Issa, Hussein A. Abbas, Tapan M. Kadia, Kelly S. Chien, Guillermo Montalban-Bravo, Rebecca Garris, Farhad Ravandi, Elias Jabbour, Nicholas J. Short

Blood (2024) 144 (Supplement 1): 728.

https://doi.org/10.1182/blood-2024-207745

Published: 2024

Journal Articles

Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features

Walid Macaron, Elias Jabbour, Nitin Jain, Fadi G. Haddad, Jayastu Senapati, Partow Kebriaei, Eitan Kugler, Kelly S. Chien, Ghayas C. Issa, Jairo Matthews, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian, Nicholas J. Short

Blood (2024) 144 (Supplement 1): 727.

https://doi.org/10.1182/blood-2024-203929

Published: 2024

Journal Articles

Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease

Blood (2024) 144 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2024-202429

Published: 2024

Journal Articles

Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission

Blood (2024) 144 (Supplement 1): 4277.

https://doi.org/10.1182/blood-2024-198928

Published: 2024

Journal Articles

Interim Results of the Phase II Study Investigating CPX-351 in Combination with Ivosidenib for Patients with IDH1-Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Jennifer Croden, Danielle Hammond, Kelly S. Chien, Abhishek Maiti, George Donovan Tippett, Guillermo Montalban-Bravo, Michael Morales, Nicholas J. Short, Hussein A. Abbas, Ghayas C. Issa, Tapan M. Kadia, Gautam Borthakur, Farhad Ravandi, Courtney D. DiNardo

Blood (2024) 144 (Supplement 1): 4271.

https://doi.org/10.1182/blood-2024-207476

Published: 2024

Journal Articles

Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 3204.

https://doi.org/10.1182/blood-2024-208890

Published: 2024

Journal Articles

Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Emmanuel Almanza, Wei-Ying Jen, Courtney D. DiNardo, Kelly S. Chien, Danielle Hammond, Yesid Alvarado Valero, Naveen Pemmaraju, Lucia Masarova, Sherry Pierce, Naval Daver, Alex Bataller, Guillermo Garcia-Manero, Amin M. Alousi, Nicholas J. Short, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 1511.

https://doi.org/10.1182/blood-2024-209558

Published: 2024

Journal Articles

Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)

Anuya A. Natu, Clifford M. Csizmar, Terra L. Lasho, Rashmi Kanagal-Shamanna, Sanam Loghavi, Alexandre Bazinet, Kelly S. Chien, Danielle Hammond, Christy Finke, Aref Al-Kali, Hassan B Alkhateeb, Naseema Gangat, Abhishek A. Mangaonkar, Antoine N. Saliba, Ayalew Tefferi, Guillermo Garcia-Manero, Hagop Kantarjian, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 4593.

https://doi.org/10.1182/blood-2024-209236

Published: 2024

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Blood (2024) 144 (Supplement 1): 4584.

https://doi.org/10.1182/blood-2024-210646

Published: 2024

NARROW

Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)

Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation

Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes

A Single-Cell T-Cell Reference Map Delineates the Biological Landscape of CD4 + T Cells in Myelodysplastic Syndromes Under Venetoclax Therapy

Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse

A Phase I/II Study of Mini-Hyper-CVD, Venetoclax and Navitoclax in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)

Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML

Outcomes of Patients with Treated Secondary AML: A High Risk Subtype of AML Arising from Previously Treated Myeloid Neoplasms That Warrants an Independent Prognostic Designation

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Older Age and TP53 Mutations Are Predictors for the Development of Therapy-Related Myeloid Neoplasms in Adults Undergoing Frontline Therapy for Acute Lymphoblastic Leukemia

Early Achievement of Deep Measurable Residual Disease (MRD) Negativity Identifies Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) Who Have Excellent Long-Term Outcomes and Do Not Benefit from Allogeneic Stem Cell Transplant, Irrespective of Baseline High-Risk Cytomolecular Features

Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease

Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission

Interim Results of the Phase II Study Investigating CPX-351 in Combination with Ivosidenib for Patients with IDH1-Mutated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia

Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Predictors of Blast Transformation (BT) and Post-BT Survival in Chronic Myelomonocytic Leukemia (CMML)

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only